Rubinstein-Taybi syndrome due to EP300 haploinsufficiency: genes and variants
Explore variant evidence for Rubinstein-Taybi syndrome due to EP300 haploinsufficiency across 1 analyzed protein (EP300). Linked ClinVar records include 17 pathogenic or likely pathogenic variants, 315 variants of uncertain significance and 89 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Rubinstein-Taybi syndrome due to EP300 haploinsufficiency
EP300: Histone acetyltransferase p300
It acetylates histones and transcription factors and acts as a central coactivator for developmental and stress-responsive transcription. Germline loss-of-function variants cause Rubinstein-Taybi syndrome type 2, while acquired alterations occur in several cancers.
17 ClinVar pathogenic / likely pathogenic and 404 uncertain variants in EP300 have source records linked to Rubinstein-Taybi syndrome due to EP300 haploinsufficiency. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): PANK2.
Where Rubinstein-Taybi syndrome due to EP300 haploinsufficiency variants cluster
- EP300 CBP/p300-type HAT (positions 1287–1663): 10 of 17 ClinVar pathogenic / likely pathogenic variants, 3.8× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Rubinstein-Taybi syndrome due to EP300 haploinsufficiency
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| EP300 M1588T | 1588 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★★) |
| EP300 F1595V | 1595 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★★) |
| EP300 T887I | 887 | Pathogenic / likely pathogenic (★★) | |
| EP300 N1286S | 1286 | Pathogenic / likely pathogenic (★★) | |
| EP300 R1831T | 1831 | Pathogenic / likely pathogenic (★) | |
| EP300 R1831S | 1831 | Pathogenic / likely pathogenic (★) | |
| EP300 R1829P | 1829 | Pathogenic / likely pathogenic (★) | |
| EP300 R580Q | 580 | KIX | Pathogenic / likely pathogenic (★) |
| EP300 R1197W | 1197 | Pathogenic / likely pathogenic (★) | |
| EP300 G1375V | 1375 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| EP300 T1411I | 1411 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| EP300 P1440T | 1440 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| EP300 H1451Y | 1451 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| EP300 F1504C | 1504 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| EP300 D1507E | 1507 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| EP300 R1627W | 1627 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| EP300 R1391S | 1391 | CBP/p300-type HAT | Pathogenic / likely pathogenic |
Which prediction tools work for Rubinstein-Taybi syndrome due to EP300 haploinsufficiency
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- ESM1b (LLR): 97 out of 100
- CATVariant: 97 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 96 out of 100
- MetaLR: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 95 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- PolyPhen-2: 92 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 85 out of 100
Same protein, different disease
- Menke-Hennekam syndrome also has ClinVar records linked to EP300 variants; they fall mostly in different places as the Rubinstein-Taybi syndrome due to EP300 haploinsufficiency variants (4 pathogenic / likely pathogenic).
Diseases related to Rubinstein-Taybi syndrome due to EP300 haploinsufficiency
- Rubinstein-Taybi syndrome due to CREBBP mutations, also linked to EP300
- Colorectal cancer, also linked to EP300
- Menke-Hennekam syndrome, also linked to EP300
- Urinary bladder cancer, also linked to EP300
- Rubinstein-Taybi syndrome, also linked to EP300
- Colon carcinoma, also linked to EP300
- Rare genetic intellectual disability, also linked to EP300
- Head and neck squamous cell carcinoma, also linked to EP300
Frequently asked questions
Which genes have records linked to Rubinstein-Taybi syndrome due to EP300 haploinsufficiency?
This view contains 1 analyzed proteins: EP300. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 17 pathogenic or likely pathogenic variants, 315 variants of uncertain significance and 89 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 667 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center